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1. Introduction 
Early and accurate diagnosis of patients with cerebral demyelinating or infection diseases, 
space occupying mass lesions and neurological deficits, is essential for optimum treatment 
decision concerning the administration of specific medication or chemotherapeutic agents, 
radiation therapy and/or surgical resection.  
Currently, conventional MR imaging (MRI) is considered to be an established and useful 
tool in brain disease detection and it is widely chosen as the initial examination step in 
patients suspected of brain lesions as it is effective in simultaneously characterizing the soft 
tissue, cerebrospinal fluid (CSF) spaces, and blood vessels. It is a flexible imaging modality 
for which contrast can be extensively manipulated without patient burdening by ionizing 
radiation. Nevertheless, the accurate characterization of brain lesions with MR imaging 
remains problematic in several cases as the sensitivity and specificity with which this 
modality defines several brain lesions remains limited [1].  
To overcome the aforementioned limitation, the development of new imaging techniques is 
required, in order to highlight functional or metabolic properties of brain tissue. Proton 
Magnetic resonance spectroscopy (1H-MRS) is one such technique which provides a non-
invasive method for characterizing the cellular biochemistry which underlies brain 
pathologies, as well as for monitoring the biochemical changes after treatment in vivo. It is 
considered as a bridge between metabolism and the anatomic and physiological studies 
available from MRI [2].  
Until now, 1H-MRS has been used as both a research and a clinical tool for detecting 
abnormalities -visible or not yet visible- on conventional MRI. Suggestively, Moller-
Hartman et al. reported that when only the MR images used for radiological diagnosis of 
focal intracranial mass lesions, their type and grade were correctly identified in 55% of the 
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cases, however, the addition of MR spectroscopic information significantly raised the 
proportion of correctly diagnosed cases to 71% [3]. 
1H-MRS has been always challenging in terms of its technical requisites (field strength, 
gradients, coils and software), as well as the accurate metabolic interpretation with regards 
to pathologic processes. However, the clinical applications of 1H-MRS are continuously 
increasing as the clinical hardware have become more robust and user-friendly along with 
improved data analysis, spectra post-processing techniques and metabolite interpretation 
confidence.  
The purpose of this chapter is to provide a thorough review concerning the current status of 
1H-MRS in terms of its clinical usefulness as well as its technical prerequisites.  
2. Basic principles 
In order to introduce the basic concepts and terminology of 1H -MRS, the basic principles of 
MRS are briefly described below.  
Proton is a charged particle with spin, and exhibits the electromagnetic properties of a 
dipole magnet. When protons are placed in an external magnetic field B0, they align 
themselves along the direction of the field (either parallel or anti-parallel) and demonstrate a 
circular oscillation. The frequency of this circular motion (called Larmor frequency) is 
dependent on the strength of the local magnetic field and the molecular structures at which 
protons belong. This can be expressed by the Larmor equation: 
0 0ω γB   
where ω0 is the Larmor frequency, γ is the gyromagnetic ratio specific for the nuclei, and B0 
is the strength of the external magnetic field.  
When electromagnetic energy (in the form of a RF pulse) is supplied at this frequency, the 
molecules absorb this energy and change their alignment. When the RF pulse is switched 
off, the molecules realign themselves to the magnetic field by releasing their absorbed 
energy. This released energy is the basis of the MR signal [4].  
1H-MRS uses the same hardware as conventional MRI, however, their main difference is 
that the frequency of the MR signal is used to encode different types of information. MRI 
generates structural images, whereas 1H-MRS provides chemical information about the 
tissue under study.  
Although recent studies have shown promise for the use of 1H-MRS to investigate malignant 
processes to prostate [5], breast [6], skeletal muscles [7], cervical and ovarian cancer [8], the 
overwhelming number of applications have been demonstrated in the brain, due to the 
absence of free lipid signals in normal cerebrum, relative ease of shimming, and lack of 
inherent motion artifacts.  
The output of 1H-MRS is a spectrum which is described by two axes as it is illustrated in 
figure 1. The vertical axis (y) represents the signal intensity or relative concentration for the 
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various cerebral metabolites and the horizontal axis (x) serves to describe the frequency 
chemical shift in parts per million (ppm). The nature of the chemical shift effect is to 
produce a change in the resonant frequency for nuclei of the same type attached to different 
chemical species. It is due to variations in surrounding electron clouds of neighboring 
atoms, which shield nuclei from the main magnetic field (B0). The resulting frequency 
difference can be used to identify the presence of important chemical compounds.  Within 
the spectrum, metabolites are characterized by one or more peaks with a certain resonance 
frequency, line width (full width at half maximum of the peak’s height, FWHM), line shape 
(e.g., lorentzian or Gaussian), phase, and peak area according to the number of protons that 
contribute to the observed signal. By monitoring those peak factors, 1H-MRS can provide a 
qualitative and/or a quantitative analysis of a number of metabolites within the brain if a 
reference of known metabolite concentration is used at a particular field strength [9]. 
  
Figure 1. Proton MR spectrum from Parietal White Metter measured at 3T in the normal human brain 
of a 19-year-old volunteer.  
3. Neurospectroscopy biochemical features and their clinical significance 
Accurate classification of cerebral lesions by in-vivo 1H-MRS requires determination of the 
relationship between metabolic profile and pathologic processes. 
The assignment and clinical significance of the basic resonances in a spectrum as well as the 
less commonly detected compounds are discussed below: 
N-Acetyl Aspartate (NAA) in 1H-MR spectra of normal cerebral tissue, is the most prominent 
resonance which originates from the methyl group of NAA at 2.01ppm with a contribution 
from neurotransmitter N-aspartyl-glutamate (NAAG) (figure 1). NAA is exclusively 
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localized in central and peripheral nervous system and it is synthesized in brain 
mitochondria. Its concentration subtly varies in different parts of the brain [10] and 
undergoes large developmental changes, increasing from 4.82mM at birth to 8.89mM in 
adulthood. Although NAA is considered as a neuronal marker and equate with neuronal 
density and viability, its exact function remains largely unknown.  
The utility of NAA, as an axonal marker is supported by the loss of NAA in many white 
matter diseases, including leukodystrophies [11], multiple sclerosis (MS) [12] and hypoxic 
encephalopathy [13], chronic stages of stoke [14] and tumors [1, 2, 9]. However, there are 
cases when the abnormal levels of NAA do not reflect changes in neuronal density, but 
rather a perturbation of the synthetic and degradation pathways of NAA metabolism. For 
instance, in Canavan’s disease high levels of intracellular NAA [15] are due to 
aspartoacylase (ASPA) deficiency, which is the enzyme that degrades NAA to acetate and 
aspartate.  
Further examples that show the lack of direct relationship of NAA to neuronal integrity 
include various pathologies such as temporal lobe epilepsy (TLE) [16] or amyotrophic lateral 
sclerosis (ALS) [17], which exhibit spontaneous or treatment reversals of NAA to normal 
levels. 
Choline-containing compounds comprise signals from free choline (Cho), phosphocholine (PC) 
and glycerophosphocholine (GPC), with a resonant peak located at 3.22 ppm. Since the 
resonance contains contributions from several methyl proton choline-containing 
compounds, it is often referred as “total Choline” (tCho). tCho is involved in pathways of 
phospholipid synthesis and degradation thus reflecting a metabolic index of membrane 
density and integrity as well as membrane turnover [1, 2, 9].  
Consistent changes of tCho signal have been observed in a large number of cerebral 
diseases. Processes that lead to elevation of tCho include accelerated membrane synthesis of 
rapidly dividing cancer cells in brain tumors [1, 2, 9], cerebral infractions, infectious diseases 
[18], and inflammatory-demyelinating diseases [19]. 
Unlike to NAA, which is distributed almost homogeneously throughout the healthy brain, 
tCho exhibits a marked regional variability with higher concentrations observed in the pons 
and lower levels in the vermis and dentate [20]. Therefore, detailed knowledge about 
regional variations of tCho is necessary for an accurate interpretation of the metabolite’s 
levels, especially in diseases such as epilepsy and psychiatric disorders where tCho is subtly 
different to normal levels.  
Creatine (Cr) and Phosphocreatine (PCr) together they are often referred as total creatine (tCr) 
because they cannot be distinguished with standard clinical MR unit (up to 7T) and their 
sum is thus mentioned. Cr and PCr arise from the methyl and methylene protons of Cr and 
phosphorylated Cr. Within the 1H-MR spectrum, tCr is located at 3.03 ppm and 3.93 ppm 
resonant frequencies. 
In the brain tCr is present in both neuronal and glial cells and is involved in energy 
metabolism serving as an energy buffer via the creatine kinase reaction retaining constant 
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ATP levels and as an energy shuttle, diffusing from the energy producing (i.e. 
mitochondria) to energy utilizing sites (i.e. nerve terminals in brain) [21]. As tCr is not 
naturally produced in the brain, its concentration is assumed to be stable with no changes 
reported with age or a variety of diseases and is used for calculating metabolite ratios 
(NAA/Cr, tCho/Cr etc) [21]. Nevertheless, the use of tCr as an internal concentration 
reference should be used with caution as decreased tCr levels have been observed in the 
chronic phases of many pathologies including tumors [22], stroke [23] and gliosis [24].  
myo-inositol (mI) is a cyclic sugar alcohol that gives rise to four groups of resonances with the 
larger and most important signal occurring at 3.56 ppm. It is observable on short time echo 
(TE) spectra as it exhibits short T2 relaxation times and is susceptible to dephasing effects 
due to J-coupling. The exact function of mI is uncertain, however it has been proposed as a 
glial marker and an increase of mI levels is believed to represent glial proliferation or an 
increase in glial cell size, both of which may occur in inflammation [2].  Additionally, this 
metabolite is involved in the activation of protein C kinase which leads to production of 
proteolytic enzymes found in malignant and aggressive cerebral tumors, serving as a 
possible index for glioma grading [25]. mI has also been labeled as a breakdown product of 
myelin. Thus, altered levels of mI have been also encountered in patients with degenerative 
and demyelinating diseases [12, 15]. 
Lactate and Lipids, in the normal brain should be maintained below or at the limit of 
detectability within the 1H-MR spectrum, overlapping with macromolecule (MM) 
resonances at 1.33ppm (doublet) and 0.9-1.3 ppm respectively. Any detectable increase in 
lactate and lipids can therefore be considered abnormal. Lactate is present in both 
intracellular and extracellular spaces and provides an index of metabolic rate and clearance 
[22].  As an end-product of anaerobic glycolysis, increased lactate levels have been observed 
in a wide variety of conditions in which oxygen supply is restricted such as in both acute 
and chronic ischemia [14], metabolic disorders [2], and tumors [1, 2, 9, 22]. Lactate also 
accumulates in tissues that have poor washout like cysts [26] and normal pressure 
hydrocephalus [27]. However, in CSF, lactate may be detectable at low levels in normal 
subjects with prominent ventricles [4].  
The spectral region between 0.9ppm and 1.3ppm as referred above; represents the 
methylene (1.3ppm) and the methyl (0.9ppm) groups of fatty acids. It is during membrane 
breakdown when fractured proteins and lipid layers become visible. Regardless of the exact 
molecular source, an elevation of lipid resonances indicates cerebral tissue destruction such 
as infarction [14], acute inflammation [28] and necrosis [18]. In addition, lipid signals have 
been observed in patients with several metabolic disorders such as Zellweger syndrome and 
Refsum’s disease [29]. 
Glutamate (Glu) and Glutamine (Gln) together they form a complex of peaks (Glx complex) 
between 2.15 ppm and 2.45 ppm, as their similar chemical structures, renders their 
distinction difficult within a proton spectra at 1.5T. However, at 3T and above Glu and Gln 
start to become resolved [30] and at magnetic fields of 7T and higher, the Glu and Gln 
resonances are visually separated leading to big quantification accuracy [21]. Glu is the 
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major excitatory neurotransmitter in mammalian brain and the direct precursor for the 
major inhibitory neurotransmitter, γ-aminobutyric acid (GABA). The amino acid Gln, is an 
important component of intermediary metabolism, is primarily located in astroglia and it is 
synthesized from Glu [21].  
The Glx complex plays a role in detoxification and regulation of neurotransmitters. 
Increased levels of Glx complex are markers of epileptogenic processes [31] and low levels 
of Glx have been observed in Alzheimer Dementia and patients with chronic Schizophrenia 
[32]. Glx complex increment, has been also observed in the peritumoral brain edema 
correlated with neuronal loss and demyelination [33]. As reported by Malhorta et al., Glx 
might be used as an in vivo index of inflammation since they observed elevated Glx levels in 
acute MS plaques but not in chronic ones [34]. 
Alanine (Ala) is an amino acid present in the normal brain, resonating at 1.47 ppm. It is 
frequently considered as a specific metabolic charecteristic of meningiomas, however, its 
identification rate varies from 32% to 100% [3, 22]. It can be also presented in neurocytomas 
[35], gliomas and PNETs [36]. In vivo 1H-MRS at 1.5T often cannot provide a distinction 
between Ala and Lac peaks as they resonate in neighboring frequencies. When both 
metabolites are present they produce a triplet peak located between 1.3 ppm and 1.5 ppm 
[37] observed at 3T and higher. 
Glycine (Gly) is the simplest amino acid and possible antioxidant, distributing mainly in 
astrocytes and glycinergic neurons, where it is regulated due to its neuroactive properties as 
an inhibitory neurotrasmitter [28]. It resonates at 3.55 ppm and it overlaps with mI 
rendering the observation of Gly impossible in a non-processed spectrum. In cases of mI 
absence, the even low Gly levels can be quantified [38].  
High levels of Gly have been observed in glioblastomas, medulloblastomas, ependymomas 
and neurocytomas [28]. It has also been reported that this metabolite may provide a 
noticeable metabolic index for the differentiation of glioblastomas from lower grade 
astrocytomas, primary gliomas from recurrence [38] and glial tumors from metastatic brain 
tumors [36].  
Taurine (Tau) gives two triplets at 3.25 ppm and 3.42 ppm, which can be observed at higher 
magnetic fields [21] as they significantly overlap with Cho and mI. Tau is an inhibitory 
neurotransmitter that activates GABA-a receptors or strychnine-sensitive glycine receptors 
and it has also been proposed as an osmoregulator and a modulator of neurotransmitter 
action [21]. High levels of Tau have been observed in medulloblastoma, pituitary adenoma 
and metastatic renal cell carcinoma [39]. Shirayama et al have been also reported increased 
levels of Tau in the medial prefrontal cortex in schizophrenic patients [40]. 
Glutathione (GSH) is the major protective molecule of living cells assigned to 2.9 ppm. It 
serves as an antioxidant and detoxifier thus having an important role against oxidative 
stress [41]. Glutathione also plays a role in apoptosis and amino acid transport [42]. 
Altered levels of this metabolite have been reported in acute ischemic stroke patients as 
ischemia is associated with significant oxidative stress [41], in Parkinson’s disease and other 
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neurodegenerative diseases affecting the basal ganglia [21]. GSH has been also found to be 
significantly elevated in meningiomas when compared to other tumors [42], showing as well 
an inverse relationship with glioma malignancy. 
Several other amino Acids such as Succinate at 2.4 ppm, Acetate at 1.92 ppm, Valine and 
Leucine at 0.9 ppm together with Alanine and Lactate, are the major spectral findings of 
bacterial and parasitic diseases. Acetate and Succinate are presumably originating from 
enhanced glycolysis of the bacterial organism [9]. The amino acids Valine and Leukine are 
known to be the end-products of proteolysis by enzymes released in pus [9]. Specifically, 
Leucine and Valine peaks have been detected in cystercercosis lesions, however they have 
not been reported in proton MR spectra of brain tumors [9].  
4. Technical considerations 
In order to precisely identify the metabolite peaks within a spectrum, several technical 
considerations should be taken into account concerning the applied magnetic field, the 
shimming procedures as well as the adequate voxel positioning and the available 1H-MRS 
techniques , which all highly affect the quality of the yielded spectrum before any post-
processing intervention. 
4.1. Field strength 
In 1H-MRS clinical applications, it is not the signals of water and fat that are of interest, but 
rather the smaller signals of metabolites, thus a magnetic field of sufficient strength is 
required. Therefore, most clinical 1H-MRS measurements are performed using MR systems 
with field strengths of 1.5T and higher. Although more powerful 4-, 6-, 7- , and even 8T MR 
body scanners are currently in use, the most common high field systems operate at 3T. The 
main advantage of increasing magnetic field strength is the subsequent increase of the 
signal-to-noise ratio (SNR). Theoretically, SNR increases proportionally to field strength, 
however, when put into clinical practice, the study of Barker et al [43], demonstrated a 28% 
increase in SNR at 3T compared to that of 1.5T at short TEs, appreciably less than the 
theoretical 100% improvement. Another advantage of magnetic field increment, is the 
proportional increase of the Chemical Shift, from 220 Hz at 1.5T to 440 Hz at 3T. This is 
reflected by more effective water suppression and improved baseline separation of J-
coupled metabolites such as glutamate, glutamine and GABA, without the need of 
sophisticated spectral editing techniques [44]. The improvement in spectral resolution is 
further evident at 7T where weakly represented neurochemicals with important clinical 
impact, such as scyllo-Ins, aspartate, taurine and NAAG, can be clearly visible [44].  
On the other hand, the aforementioned advantages may be hampered by intrinsic field-
dependent technical difficulties that should be considered. When the frequency shift 
between two adjacent nuclei is large enough, a measurable alteration of MR signal, used to 
encode the x- and y-axis spatial coordinates, will occur producing a spatial misregistration. 
This means that the volume of MRS information may not be the same as that displayed on 
the localizer MR image [45]. J-modulation anomalies represent another difficulty 
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encountered at high magnetic fields. The large separation of coupled resonances such as 
Lactate can result in incomplete inversion of the coupled spin over a large portion of the 
selected volume, resulting in anomalous intensity losses at long echo times. Strategies to 
quantify the lactate signal loss have been previously discussed by Lange et al. [46]. Magnetic 
susceptibility from paramagnetic substances and blood products, are sensibly increased 
with increasing magnetic field strength. Consequently, magnetic field inhomogeneity and 
susceptibility artifacts makes more difficult to obtain good-quality spectra, especially from 
largely heterogeneous lesions [45]. Improved local shimming methods can alleviate the 
problem. 
4.2. Shimming 
Shimming refers to the process of adjusting field gradients, either manually or 
automatically, in order to optimize the magnetic field homogeneity over the volume under 
study. Magnetic field inhomogeneities result primarily from susceptibility differences 
between different tissues and between tissue and air cavities, which are scaled non-linearly 
in ultra-high magnetic fields [47]. Thus, voxels that are placed in inhomogeneous regions of 
the brain, such as the temporal poles, are difficult to shim due to their close proximity to the 
sinuses. 
Field homogeneity is specified by measuring the full width at half maximum (FWHM) of 
the water resonance, which determines the spectral resolution. Special emphasis, especially 
when field is increased, must be placed on shimming, as it increases both sensitivity and 
spectral resolution. This is why most devices come equipped with second or third order 
shimming by monitoring either the time domain or frequency domain of the 1H-MRS signal 
[48]. Some times 4-order shimming might be necessary [49], especially in cases when field 
homogeneity should be reached in large volumes of interest during magnetic resonance 
spectroscopic imaging (MRSI).  
Effective shimming requires methods for mapping field’s strength variations over the area 
under study. Methods that have been developed for field mapping can be grouped in two 
categories: those which are based on 3D field mapping [49] and those which map the 
magnetic field along projections [50]. In both shimming methods, information about the 
magnetic field variation is calculated from phase differences acquired during the evolution 
of the magnetization in a non-homogeneous field.  
4.3. Voxel positioning 
For a meaningful in vivo 1H-MRS, it is important to locate the voxel in the appropriate 
region for a reliable metabolic characterization of a lesion [48]. 
First and foremost, cautious spatial localization is used to remove unwanted signals from 
outside the ROI, like extracranial lipids and to avoid “partial volume effects”, thereby 
providing a more genuine tissue characterization.  Additional benefits from careful spatial 
voxel localization, originate from the fact that variations in the main magnetic field and 
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magnetic field gradients, are greatly reduced, thereby providing narrower spectral lines and 
more uniform proton excitation.  
Several lesions and stroke infarcts do not always place themselves in positions that are easy to 
shim such as temporal lobes, the base of the brain and the cortex near the scull. Small voxels is 
those regions are easier to shim, but the signal also depends on volume so a voxel with 1-cm 
sides is often considered the practical minimum size to achieve a reasonable SNR [51].  
4.4. 1H-MR spectroscopy data acquisition techniques 
Spectra can be acquired either with a single voxel (SV) technique (single voxel spectroscopy, 
SVS) or multiple voxels technique, known as either magnetic resonance spectroscopic 
imaging (MRSI) or chemical shift imaging (CSI) in two or three dimensions. SVS is based on 
the stimulated echo acquisition mode (STEAM) [52] or the point resolved spectroscopy 
(PRESS) [53] pulse sequences while MRSI uses a variety of pulse sequences (Spin Echo, 
PRESS etc.) [54].  
SVS acquires a spectrum from a small volume of tissue located at the intersection of three 
mutual orthogonal slice-selective pulses as depicted in figure 2. The pulse sequence is 
designed to collect only the echo signal from the point where all three slices intersect [53].  
 
Figure 2. Schematic representation of the three orthogonal SV slice selective pulses (left) resulting in the 
signal collection only from the rectangular region of interest. 
The advantages of this approach are that: 
1. the volume is typically well-defined with minimal contamination (e.g. extracranial 
lipids),  
2. the magnetic field homogeneity across the volume can be readily optimized, leading to  
3. improved water suppression and spectral resolution.  
The main disadvantage of SVS is that it does not address spatial heterogeneity of spectral 
patterns and in the context of brain tumors, these factors are particularly important for 
treatment planning such as radiation or surgical resection. 
Lesion’s heterogeneity is better assessed by MRSI. MRSI techniques have been extended to 
two dimensions (2D) by using phase-encoding gradients in two directions, or, subsequently, 
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three-dimensional (3D) encoding [55]. Thus, the detection of localized 1H-MR spectra from a 
multidimensional array of locations is allowed (Figure 3). While technically more 
challenging -due to (1) significant magnetic field inhomogeneity across the entire area of 
interest, (2) spectral degradation due to intervoxel contamination the so called “voxel 
bleed”, (3) long data acquisition times and (4) post-processing of large multidimensional 
datasets- MRSI can detect metabolic profiles from multiple spatial positions, thereby 
offering an unbiased characterization of the entire object under investigation.  
 
Figure 3. An example of 2D-MRSI of a 50-year old female with a glioblastoma. Simultaneously acquired 
spectra from multiple regions located at the same plane of the lesion (left). Data are also presented as a 
metabolic map of Choline/Creatine (right).  
4.5. Water and lipid suppression techniques 
Water and peri-cranial lipid suppression techniques are of paramount importance in 1H-
MRS procedure in order to observe the much less concentrated metabolite signals. The 
metabolites of interest are usually about a factor of 8,000 less in concentration than water. 
Therefore, the water suppression efficiency should be robust and should not vary spatially 
across the field of view (FOV). 
The existing water suppression techniques can be divided into three major groups, namely: 
(1) methods that employ frequency-selective excitation and/or refocusing pulses; or (2) 
utilize differences in relaxation parameters; and (3) other methods, including software-based 
water suppression. The most common method of the first group utilizes multiple (typically 
3) frequency-selective, 90° pulses (chemical shift selective water suppression (CHESS) pulses 
[56], prior to localization pulse sequence. Additionally suppression can be achieved by 
selectively diphase water, while metabolites of interest are rephased using refocusing pulses 
during the spin echo period [57]. As water and metabolites T1s are sufficiently different, it is 
possible to suppress the water signal and observe the metabolites in the close proximity to 
the water resonance [58]. The third method involves the acquisition of two separated scans 
in which the metabolite resonances are inverted. The large (unsuppressed) water resonance, 
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as well as the water-related sidebands, is not inverted in either scan. The difference between 
the two scans therefore results in a water-subtracted (suppressed) metabolite spectrum 
without any interfering water-related sidebands [21]. 
Lipid suppression can be performed by avoid the excitement of the lipid signal using 
STEAM or PRESS localization to select a relatively large rectangular volume inside the 
brain. Since the extracranial lipids are not excited they do not contribute to the detected 
signal. Opposite to the strategy employed by volume pre-localization, outer volume 
suppression pulses (OVS) are applied to presaturate the lipid signal [54]. As illustrated in 
figure 4, rather than avoiding the spatial selection of lipids, OVS excites narrow slices 
centered the brain’s lipid-rich regions. Additionally, the difference in T1s of lipids (250-350 
msec) and metabolites (1000-2000msec) allows the application of an inversion pulse 
(inversion time ~ 200 msec), which will selectively null the lipid signal [59]. By choosing the 
inversion delay such that the longitudinal lipid magnetization is zero, the lipids are 
effectively not excited. 
 
Figure 4. The location and orientation of OVS pulses have been prescribed in order to saturate as much 
peri-cranial lipid as possible while the signal within the voxel remains unperturbed. 
5. Post processing techniques 
In MR spectroscopy, post-processing is considered any signal manipulation performed in 
order to improve the visual appearance of the MR spectrum or the accuracy during 
metabolite estimation. Therefore, for a reliable analysis of in vivo 1H-MR spectra, an 
understanding of the principles of post-processing techniques is necessary.  
Signal post-processing can be performed either on time domain or after Fourier 
transformation on frequency domain [60]. Eddy current correction, removal of unwanted 
spectral components, signal filtering, zero filling, phase correction and baseline correction, 
consist the most common post-processing techniques for effective signal improvement, and 
they will be briefly discussed below: 
During signal localization RF pulses are applied together with magnetic field gradients. The 
switching pattern of the gradients applied, can cause eddy current (EC) artifacts that are 
time and space dependent, causing time dependent phase shifts in the FID and distorted 
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metabolite lineshapes within the spectrum preventing accurate quantification. In a spectrum 
EC artifacts can be removed by acquiring an additional FID without water suppression. The 
phase of the water FID is determined in each time point and it is subtracted from the phase 
of the corrupted FID [24]. The EC artifact correction comprises the first step of the post-
processing procedure.  
The removal of unwanted signals from the FID which may disturb signals from the 
resonances of interest is the next step of signal post processing. A typical example of such an 
unwanted signal in 1H-MRS is that of water. Water suppression during measurement is 
never perfect and a residual water signal remains in the spectrum which often has a 
complicated lineshape [24]. Residual water elimination from the FID can be achieved, either 
by approximating the water signal and subtract it from the FID, or by eliminate it using 
special filters [61], or by applying baseline correction for the removal of the broad water 
peak from the spectrum [62].  
The existence of a distorted spectral baseline hampers quantitative analysis as the estimation 
of metabolite peak areas is not reliable. The main sources of the baseline signal are fast 
decaying components with very short T2* values such as macromolecules, hardware 
imperfections, signal from the sample and as mentioned above, inefficient water 
suppression. Thus, for robust data acquisition and quantification methods, baseline 
correction is of paramount importance. Delayed acquisition (e.g. TE > 80 ms) removes the 
macromolecules due to their shorter T2 relaxation times (∼30 msec), at the expense of loss of 
information of many scalar-coupled resonances [21] which have been suggested valuable for 
tumor and stroke characterization [4, 21, 22, 24, 25, 33].  
Special functions, called filters, can be subsequently applied at the signal in the time 
domain. The goal is to enhance or suppress different parts of the FID leading to improved 
signal quality. The three most commonly used filtering approaches are: sensitivity 
enhancement, to reduce the noise from the FID; resolution enhancement, to achieve 
narrower metabolite linewidths; and apodization for signal’s ripple (due to signal 
truncation) reduction [62]. 
The FID of a spectrum, when acquired, is sampled by the analog-to-digital converter over N 
points in accordance to the Nyquist sampling frequency. Therefore, if the number of points 
is not sufficient, the reliable representation of the signal fails. Instead of increasing the 
acquisition time with the inevitable noise increment, the acquired FID can artificially be 
extended by adding a string of points with zero amplitude to the FID prior to Fourier 
Transformation, a process known as zero filling. Zero filling does not increase the 
information content of the data but it can greatly improve the digital resolution of the 
spectrum and helps to improve the spectral appearance [21], rendering it an important post-
processing step. 
After Fourier transformation, the spectrum will be phase corrected. When the zero-phased 
FID signal shifts to the frequency domain, yields a complex spectrum with absorption (real) 
and dispersion (imaginary) Lorentz peaks. However, when the initial phase is non-zero, it is 
not attainable to restore pure absorption or dispersion line shapes and phase correction 
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must be applied [4, 21, 62]. A zero-order phase correction compensates for any mismatch 
between the quadrature receive channels and the excitation channels to produce the pure 
absorption spectrum, whereas, a first-order phase correction compensates for the nuclei 
dephase due to the delay between excitation and the detection of FID [62].  
6. 1H-MRS metabolic profiles of brain lesions 
The effective differential diagnosis of brain lesions using 1H-MRS depends on the ability of 
the experienced neuroscientist to interpret and evaluate the metabolic criteria and data 
underlying each disease. However, similarities in the chemical composition among diseases 
and/or atypical metabolic characteristics, often burden the diagnosis. Thus, a clinical guide 
to the main MR spectroscopic findings of cerebral disorders is necessary.  
This section focuses on the metabolic patterns of a variety of intra-cranial diseases.  
6.1. Multiple Sclerosis (MS)  
Multiple Sclerosis (MS) is an auto-immune inflammatory disease of the central nervous 
system (CNS) in which the myelin sheaths around the axons are damaged leading to 
demyelination, neuronal affection, inflammation, gliosis and axonal degeneration [14].  1H-
MRS is particularly informative in MS, by providing evidence of the two primary pathologic 
processes of the disease: active inflammatory demyelination and neuronal injury in both 
lesional and non-lesional brain tissue [63, 64].  
Acute demyelinating lesions reveal increased Cho and Lac resonance intensities due to the 
release of membrane phospholipids during active myelin breakdown and the impaired 
metabolism of the inflammatory cells, respectively [63]. Short TE spectra also provide 
evidence of increased lipids, mI [63, 64] and glutamate levels [34]. Increased glutamate 
levels in acute MS lesions address a link between the direct axonal injury and glutamate 
excitotoxicity [65], whereas mI is suggestive of glial proliferation and astrogliosis [63]. The 
aforementioned changes are accompanied by a substantial decrease in NAA due to axonal 
injury reflecting metabolic or structural changes [64, 65]. It is important to note that the 
spectroscopic changes seen in acute MS plaques are often very similar to the spectra 
observed in brain tumors (high Cho, low NAA, increased Lac, etc.), and therefore this 
should be kept in mind when evaluating spectra from patients with undiagnosed brain 
lesions.  
After the acute phase transition, Lac, Cho and lipids seem to return to normal levels, 
whereas NAA may remain decreased or show partial recovery, lasting for several months 
[64]. The recovery of NAA can be attributed to resolution of edema, diameter increment of 
the previously shrinked axons, as a result of the re-myelination and reversible metabolic 
changes in neurons [64, 65]. There are reports of elevated Cho resonance in chronic MS 
plaque, probably reflecting the associated gliotic process [66]. Cr seems to be a variable 
metabolite both in chronic and acute, but is also described to be slowly increasing over time, 
indicative of gliotic reaction or attempts of incomplete re-myelination of the chronic 
diseased tissue phases [14]. 
 Novel Frontiers of Advanced Neuroimaging 32 
Metabolic abnormalities in MS patients not only concern the lesions, but are found 
throughout the normal appearing white matter (NAWM) with notably reduced NAA, which 
is thought to indicate diffuse axonal dysfunction or loss. It must also be stressed out that the 
presence of intense gliosis may also cause increased levels of mI [67] and Cr [68]. Increased 
glutamate, lipids and Cho can be also found in regions of the NAWM, which later are going 
to develop T2-hyperintense focal lesions [64].   
6.2. Intracranial abscesses  
Brain abscesses are focal, intracerebral infections that begin with a localized region of 
cerebritis, evolving into a discrete collection of pus surrounded by a well-vascularized 
capsule. The causative organisms involved in brain abscesses are quite variable, and may 
consist of mixed cultures: aerobes, anaerobes, facultative anaerobes, and facultative 
anaerobes in combination with aerobes/anaerobes.  
MRS has been proven beneficial in differentiating between brain abscesses and other cystic 
lesions [69], which can be used to implement the appropriate antimicrobial therapy. Brain 
abscesses reveal specific metabolic substances, such as succinate, acetate, alanine, valine, 
pyrouvate, leukine, lipids and lactate [69, 70],which are all present in untreated bacterial 
abscesses or soon after the initiation of treatment [70]. Increases in lactate, acetate, and 
succinate presumably may originate from the enhanced glycolysis and fermentation of the 
infecting microorganisms. Amino acids such as valine and leucine are known to be the end 
products of proteolysis by enzymes released by neutrophils in pus [14]. However, cerebral 
abscesses contain no neurons [71], therefore no peaks of NAA and Cr/PCr should be 
detected. The detection of any NAA and/or Cr/PCr is indicative of either signal 
contamination or erroneous interpretation of acetate peak as NAA [72]. Similarly no tCho 
peak is present in an abscesses spectrum because there are no membranous structures in its 
necrotic core [73]. On the other hand, abscesses of tuberculous origin are characterized by 
the predominant presence of lipids, moderate increase of tCho resonance and no evidence of 
cytosolic amino acids [4]. 
Differential diagnosis of brain abscess versus brain tumor is sometimes difficult on the basis 
of imaging findings and clinical judgment, especially in the case of a brain tumor with a 
mainly cystic or necrotic component. However, because the vast majority of the 
aforementioned amino acids have not been detected in brain neoplasms, their presence 
strongly differentiates abscesses from highly aggressive tumors [71].  
6.3. Ischemia  
Most studies of 1H-MRS of the human brain have focused on the signals from NAA and 
lactate, as potential markers of brain ischemia, respectively, although there are also often 
changes in the other metabolite signals, such as Cho, Cr, glutamate (Glu) and glutathione 
(GSH) [74].  The time course of these metabolite changes through time is an important factor 
for the diagnosis and prognosis of a brain infarct.  
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In acute stroke the infarct core rapidly shows signs of cell death and a spectrum from this 
area has the characteristic lactate peak, often with a broad lipid peak too. Lactate could also 
arise from a shift toward anaerobic glycolysis in potentially viable cells that continue to 
metabolize glucose under locally hypoxic conditions [75]. Lactate may also be present in 
smaller concentrations in the ischemic penumbra, the region around the core which if 
quickly re-perfused may recover its function [75]. Lactate formed in the initial period of 
ischemia could remain in necrotic tissue and leave the region of injury after cell lysis in a 
period of weeks or months after the stroke onset.  
Unlike to the increase of lactate, NAA is observed to slowly decrease over a time scale of 
hours after the induction of ischemia [75]. Several studies have described an initial rapid 
decrease in NAA of about 10% within the first few minutes followed by a slower decrease.  
It has been suggested that NAA diminish may be due to NAA degradation by enzymes 
within the injured neurons in the first few days or hours following infarction, or perhaps 
due to changes in other molecules (e.g. Glu, Gln, GABA etc.) which overlap with the spectral 
resonance of NAA [74]. 
tCho has been observed to either increase or decrease both in acute and chronic human 
ischemia [76]. Increases in Cho in stroke may be the result of gliosis or ischemic damage to 
myelin, while decreases are probably the result of edema, necrosis and cell loss [4]. Initial 
reduction in Cr/PCr is identified following infarction and further reductions have been 
demonstrated up to ten days following the time of onset [74]. Muniz Maniega et al. reported 
continuous reduction of Cr levels over a period of three months from the stroke onset [76].  
A study by Rumpel et al. revealed that mI might also significantly contribute to the 
understanding of brain tissue response to ischemia, which is in line with a persistent 
cytotoxic swelling, attributed to the glial population, found in early subacute ischemic 
infarcts [77]. Acute ischemic also causes changes in the glutathione (GSH) system (decreased 
GSH in ischemic patients) as stroke is associated with significant oxidative stress [41]. 
Experimental studies have suggested that ischemic stroke may cause an increment in 
extracellular level of GABA; however there is very little work on the detection of GABA and 
glutamate in cerebral ischemia [78].  
6.4. Epilepsy 
The term epilepsy covers a wide group of syndromes with varied etiology and prognosis. 
By providing an insight into the biochemical processes related to epileptic seizures, 1H-MRS 
aids in the localization or lateralization of the epileptogenic foci and in the influence of the 
metabolites concentration after the administration of antiepileptic drugs and/or after 
resection of the epileptogenic tissue. 
Temporal lobe epilepsy (TLE) associated with hippocampal sclerosis (HS) is the most 
common refractory focal epilepsy. The localization is performed by the comparison of 
metabolites on the left and right temporal lobe, especially in the hippocampus and temporal 
poles, to determine which hemisphere is responsible for the genesis of seizures [79]. The 
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metabolites of interest in epilepsy are NAA, GABA and glutamine/glutamate (Glx) and the 
less prominent mI and lactate (Figure 5). Most of the studies dealing with mesial TLE, 
demonstrate decreased levels of NAA in the affected temporal lobe when compared with 
controls or with the homologous non-epileptic contralateral region, with no changes or mild 
increases of tCho. Interestingly, not only decrease of NAA content occurs in the 
epileptogenic foci, but also unilateral presence of lactate in the mesian temporal lobe could 
potentially be indicative of the side of the epileptogenic zone [16].  
Nowadays, a hypothesis exists in which the raise of mitochondrial energy consumption 
promotes a reduction of neuronal synthesis of NAA, and, therefore, an increase of glutamate 
(its precursor) [80]. In epileptic patients, it seems to exist a disequilibrium of 
glutamine/glutamate (Glx) and GABA [81]. Therefore, spectroscopic measurements of Glx 
complex could yield spatial information on the epileptogenic zone. However, although there 
is some evidence that Glx is elevated in TLE, its value as a marker for the epileptogenic zone 
has not been established yet. 
Additionally, 1H-MRS studies of TLE have also been focused on mI, however, its role 
remains controversial. The study of Wellard et al. revealed elevated mI in the epileptogenic 
temporal lobe of patients with HS [82]. They also reported a difference of mI levels between 
the seizure focus (temporal lobe) where mI is increased, and areas of seizure spread (frontal 
lobe) where mI is decreased. Thus, 1H-MRS may aid to the distinction of primary 
epileptogenic brain damage from seizure secondary effects on adjacent normal brain  and 
help to distinguish drug refractory TLE patients, who will benefit from surgery by 
predicting postoperative outcome [83].  
 
 
Figure 5. Short TE (35msec) spectra at 3T obtained in the left and right hippocampal formation from a 
patient with right HS using single-voxel technique. The decreased NAA signal and the increased mI at 
the affected region (A) are evident when compared with the contralateral normal hippocampal 
formation (B). Note the mild elevation of the Glx complex at the affected region (B). 
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6.5. Neurodegenerative diseases (Alzheimer/Parkinson)  
Numerous studies have attempted to identify specific metabolic markers for different 
neurodegenerative diseases, such as Alzheimer’s dementia (AD) and Parkinson’s disease 
(PD), which concern loss of structure or function of neurons including death of the neuronal 
cells. The clinical objective in that cases is to establish a precise and early diagnosis as well 
as to understand the related brain changes that could help to slow down the course of the 
disease [60]. 
1H-MRS has been demonstrated to be highly specific and sensitive to the diagnosis of 
Alzheimer’s dementia (AD) [15]. Reduction in NAA is the most frequent 1H-MRS finding in 
AD [84, 85]. Single Voxel 1H-MRS studies have consistently found reductions in NAA/Cr 
ratio in the hippocampal formation [85] as well as other temporal regions [86] and the 
posterior cingulate gyrus [87]. Findings of reduced NAA have been also detected in the 
temporoparietal area, and the occipital lobes [85, 87]. There have been conflicting reports 
regarding Cho levels in patients with AD. Some researchers found elevated Cho and/or 
Cho/Cr ratios in AD patients, while others not [32, 85, 87]. Increased mI has been also 
observed, most often, in the temporal-parietal area [85], the posterior cingulate gyrus [32, 86, 
87], the parietal white matter 86] and less often in the frontal lobes [86]. Few studies have 
also reported reduced Glx levels in AD patients compared to control subjects in the 
posterior cingulated gyrus [88] and lateral temporal cortex [86].  
The majority of 1H-MRS studies in Parkinson’s Disease (PD) to date have primarily targeted 
brain levels of NAA, Cr, and Cho [89, 90]. Many researchers disclosed a significant 
reduction of ratios NAA/Cr and NAA/Cho in the temporoparietal cortex [91], the substantia 
nigra, the basal ganglia [92], the striatum or the occipital lobe [93]. Griffith et al. have 
demonstrated lower NAA/Cr ratios in the posterior cingulate gyrus of demented versus non 
demented subjects with PD [94]. Other investigators, however, have not detected such 
changes [95] in NAA, Cr, and Cho measurements, and the reasons for these different 
findings need to be resolved.  
6.6. Gliomas 
Gliomas are spatially heterogeneous lesions which arise from the ‘gluey’, or supportive 
tissue of the brain. The main types of gliomas are astrocytomas, oligodendrogliomas, and 
ependymomas. 1H-MRS is increasingly used in clinical studies to non-invasively identify 
regions with metabolic specific characteristics that reflect glioma type and grade.  
A common observation in 1H-MRS of all glial tumors is a decreased levels of NAA and 
increased levels of tCho with a significant overlap among different glioma types [2, 22]. 
Thus, 1H-MRS is currently used primarily to differentiate glial tumor grade rather than to 
confirm a histopathological diagnosis [96]. 
However, the signal intensity of glutamine and glutamate (Glx) may aid the distinction 
between oligodendrogliomas and astrocytomas. Rijpkema et al. found significantly 
increased Glx levels for oligodendrogliomas when compared to that of astrocytomas [97] 
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using short TE 1H-MRS. Additionally, in a study by Majos et al, ependymomas 
differentiated well from the other glial tumors by showing prominent peaks of mI+Gly and 
Taurine at long TE spectra [98].  
Discrimination between tumor grades in gliomas is an important clinical issue, because 
there is a dispute on the optimum treatment strategy for patients with low-grade tumors. It 
remains an open question whether 1H-MRS is able to define WHO grade of gliomas. 
However, a recent study by Porto et al. revealed a more prominent loss of NAA and 
increase of tCho in WHO III over WHO II astrocytomas [99]. They consequently proposed 
NAA/tCho ratio as the most accurate index to discriminate between those tumor grades 
which is in agreement with what it is generally accepted, i.e. NAA/tCho ratios decrease with 
higher histological grade of gliomas. Law et al. demonstrated a threshold value of 1.6 for 
tCho/NAA which provided 74.2% sensitivity and 62.5% specificity in predicting the 
presence of a high-grade glioma [100]. Thus it is obvious that there is a consistent correlation 
between Cho increase as well as NAA decrease and tumor grade.  
A study by Moller-Hartmann et al. revealed that instead of tCho, the amount of lipids 
proved to be the second-best discriminator between low- and high-grade gliomas, with 
glioblastomas multiforme (GBM) to exhibit the highest amount of lipids since necrosis is one 
of their microsopic hallmarks [3].  Although it has been previously proved that lactate also 
increases with grade, it is not always significantly differentiated between high and low 
grade gliomas [22]. Poor correlation between tumor grade and lactate is most likely due to 
the difficulty of accurately quantifying lactate in the presence of high lipid signals.  
Short TE studies have also shown that mI levels may aid tumor classification and grading 
[22, 25]. Specifically, Castillo et al. retrospectively studied 34 patients with astrocytomas and 
found a trend towards lower mI levels in high-grade compared with low-grade tumors [25].  
One of the most interesting results of the study by Server et al. was the elevation in the 
peritumoral Cho/Cr and Cho/NAA metabolite ratios in relation to glioma grading [101]. 
Thereby, as gliomas are infiltrating intracerebral tumors, 1H-MRS may allow to readily 
appreciate their grade in the perifocal region.  
6.7. Cerebral metastasis 
Cerebral metastases are a common complication of cancer and can affect 20% to 40% of 
patients [102] who suffer from primary tumors in lung, breast, skin or colon.  
When a metastatic brain tumor presents as a solitary lesion, it is usually indistinguishable 
from a high grade glioma [103]. Their distinction is important because the treatment 
approach and follow-up are different for these two different tumors. 
The potential of in vivo 1H-MRS for differentiating intracerebral metastases from GBMs has 
been investigated in a number of studies [102, 104]. Older studies [22, 105] have reported 
that intratumoral 1H-MRS, either on short or long TE, was unable to differentiate between 
metastases and GBMs, as they share common metabolic features. Those concern increased 
levels of lipids and tCho and reduced levels of NAA as it is depicted in figure 6. 
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Nevertheless, a study by Moller-Hartman et al. revealed elevated lipids for metastases, with 
statistically significant difference from GBMs [3]. Opstad et al. speculated that the 
differences in lipid profiles may be related to differences of membrane structures of 
infiltrative versus migratory tumor cells [106]. Significantly higher Cho/Cr ratio for 
metastases than for GBMs was reported by Server et al. due to GBMs higher levels of 
necrosis [102]. On the contrary, Law et al. revealed significantly lower Cho/Cr ratio for 
metastases than for high grade gliomas [105]. These conflicting results may be due to the 
intrinsic heterogeneity of such tumors.  
 
 
Figure 6. Typical Short TE spectra from glioblastoma multiforme (A) and intracerebral metastases (B). 
 
 
Figure 7. Short TE spectra from peritumoral areas of glioblastoma multiforme (A) and intracerebral 
metastases (B). 
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Furthermore, promising results in differentiating between GBMs and metastases by means 
of the resonances at 3.56 ppm, represented by the sum of mI and Gly, have been previously 
observed [36]. Gly/mI showed a tendency to be higher in GBMs than in metastases. 
Measuring the peritumoral metabolites or metabolic ratios is often more useful in 
differentiating intracranial metastases from high grade gliomas with more reproducible 
results among different studies. Elevated Cho as well as reduced NAA have been found in 
the peritumoral region of high-grade gliomas, but not in the peritumoral region of 
metastases when compared to normal levels as it is illustrated in figure 7.  
Those findings support the hypothesis that the edema surrounding metastases is purely 
vasogenic, while the peritumoral region of GBMs is characterized by extensive infiltration of 
tumor cells [102, 104-106]. 
Some patients get their brain metastases detected before the primary cancer. Since GBM case 
has being withdrawn from the differential diagnosis, identification of metastases type 
would be important for further treatment. Sjobakk et al. investigated the feasibility of using 
1H-MRS to characterize brain metastases originating from different primary cancers. The 
results presented in their study, demonstrated that lipid signals on both short and long TE 
spectra are important for metastases characterization. Although non-statistically significant, 
lung metastases tended to differentiated from breast metastases in respect to their lipid 
signals, while the melanoma showed no trend [107]. Chernov et al retrospectively studied 25 
metastatic brain tumors from lungs, colon, breast, kidney, prostate and cardiac muscle, 
using 1H-MRS on long TE. The detected metabolic characteristics revealed that metastases of 
colorectal carcinoma have significantly greater lipid content, expressed as Lipids/Cr ratio, 
compared to metastatic tumors of other origin. The authors suggested an optimal Lipids/Cr 
cut off value of 2 for the identification of the colorectal carcinoma [108]. It is obvious that 1H-
MRS may aid in the determination of cerebral metastases origin, nevertheless, further 
research is needed to determine the exact role of proton MR spectroscopy in the 
identification of the tissue type of metastatic brain tumors. 
6.8. Meningiomas 
Meningiomas are common intracranial tumors and are generally easily diagnosed by their 
characteristic radiological imaging appearance of solid mushroom imaging pattern, 
extracranial location, dura matter conjunction and sinus involvement. However, 15% of 
meningiomas exhibit rim like enhancement, a prominent cystic component, hemorrhage, or 
even metaplasia [109], mimicing gliomas or cerebral metastatic tumors. 1H-MRS has been 
proved useful in differentiating meningiomas with atypical radiologic pattern from other 
brain tumors [36]. 
Alanine at 1.47ppm has been considered as the characteristic metabolic marker of 
meningiomas which differentiates them from other brain tumors [36, 38]. Nevertheless, 
reported occurrence of Alanine varies among different studies [37, 16] as it can significantly 
overlap with lactate resonance due to J-coupling effect [37].  
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In the absence of Alanine, several investigators aimed to correlate other metabolites to 
meningioma presence. Studying the metabolic profile of different cerebral tumors using 
short TE 1H-MRS, Howe et al. found that low levels of mI and Cr were characteristic for 
meningiomas relative to grade II astrocytomas, anaplastic astrocytomas and glioblastomas 
[22]. In the same study meningiomas revealed the highest Cho/Cr ratio among the other 
brain tumors, on both short and long TE. Another reported specific finding for 
meningiomas, is the absence of the neuronal marker NAA. Instead of partial volume effects 
[3], the peak of NAA at meningioma spectra, may also represent other endogenous NAA 
compounds (NACs) such as N-acetylaspartylglutamate, N-acetylneuraminic acid and N-
acetylgalactosamine [37]. 
A recent study by Kousi et al.  revealed a distinct chemical compound, observed in all 
meningiomas recruited for that study, which may establish a rather specific marker in their 
differential diagnosis from high grade gliomas and metastases [6]. This chemical substance, 
resonated at 3.8ppm using short TE 1H-MRS (Figure 8) and according to the in vitro study of 
Tugnoli et al. it might receive contribution from phosphoethanolamine (PE) and other 
amino acids such as Leukine, ALanine, Glutamate, Glutamine, Glutathione, Lysine, 
Arginine and Serine [110].  
 
Figure 8. FLAIR T2 images (left) of a meningioma with its corresponding spectrum (right), at short TE 
(35ms). Elevated Cho and lipid resonances were detected at 3.2ppm and 1.3ppm respectively, as well as 
a distinct chemical compound resonating at 3.8 ppm [6]. 
6.9. Primary Central Nervous System Lymphomas (PCNSL) 
Primary central nervous system lymphoma (PCNSL) represents 1% of all brain tumors and 
its incidence has increased in the last 3 decades. Although densely contrast-enhancing 
lesions, without the presence of necrosis are characteristic imaging features of PCNS 
lymphoma, it can be difficult, sometimes even impossible, to distinguish PCNSLs from high 
grade gliomas on conventional MRI [111]. Their differentiation, however, has important 
diagnostic and therapeutic implications.  
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For the correct diagnosis of brain lymphomas, 1H-MRS has reported promising results. The 
most specific finding for PCNSL on MRS is an increase in lipid and Cho resonances (Figure 
9).  Sometimes, lipid peaks in PCNSL may be more prominent than in high grade gliomas 
and can help differentiate between the two tumor types [107]. 
Lipids are typically a signature of cell death; however, a lipid dominated spectrum found in 
PCNSL does not indicate necrosis. This appears to be due to numerous macrophages and 
the increased turnover of membrane components in transformed lymphoid cells which 
contain high concentrations of mobile lipids [112].  
Histopathologically, PCNSLs are characterized by a diffusely infiltrative pattern and hence, 
it is important to survey the peritumoral area also and not just the area of obvious tumor 
involvement. Like high grade gliomas, the peritumoral area of PCNSLs demonstrates an 
abnormal metabolite pattern. Chawla et al. reported increased Cho/Cr and Lip+Lac/Cr ratios 
in the peritumoral area of PCNSLs. They also observed significantly higher Lip+Lac/Cr ratio 
in the peritumoral area of PCNSLs when compared with that of GBMs, suggesting the 
presence of infiltrative active lymphocytes and macrophages in areas beyond lymphoma 
boundaries. Using a threshold value of 7.09 for Lip+Lac/Cr ratio they differentiated PCNSLs 
from GBMs with 84.6% sensitivity and 75% specificity [107]. Therefore, in the absence of 
obvious necrosis, increased lipid concentration together with a markedly elevated Cho/Cr 
ratio for both intratumoral and peritumoral areas can provide important metabolic 
information which may improve the distinction between PCNSLs and other brain tumors. 
 
Figure 9. Spectra from an intracerebral lymphoma on both short (A) and long TE (B), demonstrating the 
characteristic elevation of lipid and Cho resonances.  
6.10. Central neurocytomas 
Central neurocytomas (CNCs) are a neuronal tumor almost exclusively located in the lateral 
ventricles that appear in young adults. Most of these tumors do not recur after surgery and 
are generally considered benign, with a favorable prognosis [28].  
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Instead of their typical radiological appearance - a well circumscribed lobulated mass in the 
anterior portion of the lateral ventricles– it may not always be possible to differentiate CNCs 
from other intraventricular tumors such as oligodendrogliomas and ependymomas [113].   
1H-MRS has been proved a valuable tool for the presurgical diagnosis of these neoplasms. 
Previous studies have reported CNCs to consistently show the tumoral pattern of increased 
Cho and decreased NAA levels [28, 35]. On the contrary, lactate has not been observed 
consistently in all studies. Specifically, although Kim et al. reported lactate in all of their 
patients, Shah et al. observed lactate in only 9% of the CNC cases [114, 115]. A few studies 
have speculated the rather specific marker of Gly at 3.55ppm on long TE spectra, strongly 
suggesting CNC occurrence [28, 115].  
The presence of Ala in a patient with CNC was first reported by Chuang et al. using a 3T 
MR system [116]. It was demonstrated as an inverted doublet at 1.5 ppm with a TE of 135 
msec. Similarly, Krishnamoorthy et al. also observed Ala in all three CNC cases (100%) 
studied, whereas in the study of Shah et al. Ala was observed in 64% of the CNCs [35, 115]. 
Thus, CNCs may show Ala as an inverted doublet at 1.5 ppm in long TE spectra. Although 
one may observe Ala in other intraventricular tumors such as meningioma, other 
characteristic peaks such as Gly, high Cho and decreased NAA should help to correclty 
identify CNC. 
6.11. Gliomatosis Cerebri 
Gliomatosis Cerebri (GC) is a rare brain tumor characterized by a diffuse neoplastic 
overgrowth of glial elements of various histological subtypes (astrocytoma, 
oligodendroglioma, or mixed glioma) and extensive infiltration of at least two lobes [117]. 
Unlike gliomas, the neuronal architecture is usually preserved [118]. 
MRI characteristics of GC are non-specific and occasionally it is difficult to differentiate GC 
from demyelinating diseases or viral encephalitis, and biopsy is often inconclusive [9]. 
Given the unfavorable prognosis of this tumor type, there is a demand for alternative 
imaging techniques, such as 1H-MRS, to grade GC and to detect the most anaplastic areas 
for determining surgical areas and radiotherapeutic targets.  
A few studies have looked at the spectral features of such tumors and those are consistent 
with the spectral features of gliomas discussed above. By studying 8 patients with GC using 
long TE 1H-MRS, Bendszus et al. found elevated Cho/Cr and Cho/NAA ratios, as well as 
decreased NAA/Cr ratios of varying degrees in the abnormal areas on T2-weighted images 
[119]. Similarly, a retrospective analysis by Yu et al. also revealed high Cho/Cr and 
Cho/NAA ratios and low NAA/Cr ratio within the areas of hyperintensity on T2-weighted 
images in 8 histopathologically confirmed patients with GC. Anaplastic areas had higher 
Cho/NAA ratio and the lactate doublet was present [117]. Apart from being beneficial in the 
grading of GC, 1H-MRS might reflect the true extent of neoplastic infiltration more 
accurately than MRI.  Bendszus et al. found elevated Cho/Cr and Cho/NAA ratios in the 
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tumor margins that appeared normal on T2- weighted images. Tumoral infiltration of the 
margin of the lesion that appeared normal on T2-weighted images was also confirmed by 
Yu et al. by observing increased Cho/NAA ratio in those areas [117].  
From the aforementioned findings it can be concluded that 1H-MRS when combined to MRI 
findings may aid to GC diagnosis. Additionally, the determination of highly anaplastic areas 
and areas of tumoral infiltration may have a great impact in radiotherapy planning. 
6.12. Suprasellar tumors 
Pituitary adenomas and craniopharyngiomas, are the most frequent suprasellar space 
occupying lesions and are generally regarded as benign neoplasms of the pituitary gland. 
Nevertheless, with respect to the differential diagnosis of suprasellar masses, pituitary 
adenomas, craniopharyngiomas together with gliomas and meningiomas can be considered 
[120].   
To date only a few cases of pituitary adenomas and craniopharyngiomas have been studied 
by in-vivo 1H-MRS [16, 120, 121], probably because of their relative rarity and the technical 
difficulties in obtaining in vivo high-quality spectra without artifacts is such a region [120]. 
In a study by Chernov et al., the vast majority of the 19 pituitary adenomas were 
characterized by a significant reduction of NAA peak, moderate elevation of Cho, and 
infrequent presence of small lipid and lactate peaks. This metabolic pattern differentiated 
them from low grade gliomas which showed a moderate decrease of NAA and Cr peaks. In 
the same study, craniopharyngiomas were typically characterized by a significant decrease 
of all metabolites and presence of multiple additional peaks which were possibly resulted 
from the presence of calcifications and microcysts within the investigated volume of tissue 
[16]. On the contrary, Sener et al. demonstrated very prominent peaks in the 
craniopharyngiomas between 0.5 and 1.5 ppm, which probably corresponded to lipid peaks. 
Histological findings also revealed high amounts of cholesterol, lipids and lactate in the cyst 
fluid correlating with their spectroscopic findings [120]. 
7. Conclusion 
1H-MRS can provide important in vivo metabolic information, complementing 
morphological findings from conventional MRI in the clinical setting. This technique is an 
extremely valuable tool in solving difficult neurological cases and increase confidence in 
diagnosis; however, it should be always considered a supplementary tool to the patients’ 
clinical history, examination, and conventional MRI when reaching the final diagnosis.  
The future would be to combine 1H-MRS with other advanced magnetic resonance 
techniques such as Diffusion/Diffusion Tensor Imaging and Perfusion-weighted Imaging, 
which will potentially prove to be useful in both clinical and research settings. Ultimately, 
these advanced tools may be used in a multiparametric, algorithmic fashion to characterize 
tissue biology and dramatically improve tumor differential diagnosis. 
 
Proton Magnetic Resonance Spectroscopy of the Central Nervous System 43 
Author details 
Evanthia Kousi and Ioannis Tsougos 
Medical Physics Department, School of Medicine, University of Thessaly, Larissa, Greece 
Kapsalaki Eftychia 
Radiology Department, School of Medicine, University of Thessaly, Larissa, Greece 
8. References 
[1] Nelson, S. J. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer 
Ther 2003;2(5) 497-507. 
[2] Soares, D. P. and M. Law. Magnetic resonance spectroscopy of the brain: review of 
metabolites and clinical applications. Clin Radiol 2009; 64(1) 12-21. 
[3] Moller-Hartmann, W., S. Herminghaus, et al. Clinical application of proton magnetic 
resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 
2002; 44(5) 371-81. 
[4] Jonathan H. Gillard, Adam D. Waldman, Peter B. Barker. Clinical MR Neuroimaging: 
Diffusion, Perfusion and Spectroscopy. Cambridge University Press; 2004. 
[5] Bonekamp, D., M. A. Jacobs, et al. Advancements in MR Imaging of the Prostate: From 
Diagnosis to Interventions. Radiographics 2011; 31(3) 677-703. 
[6] Kousi E, Tsougos I, Vasiou K, et al. Magnetic Resonance Spectroscopy of the Breast at 
3T: Pre- and Post-Contrast Evaluation for Breast Lesion Characterization. 
ScientificWorld Journal. 2012; 2012 754380 
[7] Lee, C. W., J. H. Lee, et al. Proton magnetic resonance spectroscopy of musculoskeletal 
lesions at 3 T with metabolite quantification. Clin Imaging 2010; 34(1) 47-52. 
[8] Pinker, K., A. Stadlbauer, et al. Molecular imaging of cancer: MR spectroscopy and 
beyond. Eur J Radiol.2012;81(3) 566-77 
[9] Sibtain, N. A., F. A. Howe, et al. The clinical value of proton magnetic resonance 
spectroscopy in adult brain tumours. Clin Radiol 2007; 62(2) 109-19. 
[10] Doelken MT, Mennecke A, et al. (2009) Multi-voxel magnetic resonance spectroscopy of 
cerebral metabolites in healthy adults at 3 Tesla. Acad Radiol 2009; 16 (12) 1493-1501.  
[11] Tavora DG, Nakayama M, et al. Leukoencephalopathy with brainstem and spinal cord 
involvement and high brain lactate: report of three Brazilian patients. Arq 
Neuropsiquiatr 2007;65 (2B) 506-511. 
[12] Wattjes MP, Harzheim M, et al. High field MR imaging and 1H-MR spectroscopy in 
clinically isolated syndromes suggestive of multiple sclerosis: correlation between 
metabolic alterations and diagnostic MR imaging criteria. J Neurol 2008;255(1) 56-639. 
[13] Rosen Y, Lenkinski RE. Recent advances in magnetic resonance neurospectroscopy. 
Neurotherapeutics. 2007;4(3) 330-45. 
[14] Mader I, Rauer S, Gall P, Klose U. (1)H MR spectroscopy of inflammation, infection and 
ischemia of the brain. Eur J Radiol 2008; 67 (2) 250-257. 
 Novel Frontiers of Advanced Neuroimaging 44 
[15] Lin A, Ross BD, Harris K, Wong W. Efficacy of proton magnetic resonance spectroscopy 
in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2005; 2 (2) 
197-214 
[16] Chernov MF, Ochiai T, et al. Role of proton magnetic resonance spectroscopy in 
preoperative evaluation of patients with mesial temporal lobe epilepsy. J Neurol Sci 
2009; 285 (1-2):212-219. 
[17] Wang S, Poptani H, et al. Amyotrophic lateral sclerosis: diffusion-tensor and chemical 
shift MR imaging at 3.0 T. Radiology 2006; 239 (3) 831-838. 
[18] Lai PH, Weng HH, et al. In vivo differentiation of aerobic brain abscesses and necrotic 
glioblastomas multiforme using proton MR spectroscopic imaging. AJNR Am J 
Neuroradiol 2008; 29 (8) 1511-1518  
[19] Hayashi T, Kumabe T, et al. Inflammatory demyelinating disease mimicking malignant 
glioma. J Nucl Med 2003; 44 (4) 565-569 
[20] Mascalchi M, Brugnoli R, et al. Single-voxel long TE 1H-MR spectroscopy of the normal 
brainstem and cerebellum. J Magn Reson Imaging 2002; 16(5) 532-537. 
[21] Robin A. de Graaf . In vivo nmr spectroscopy: Principles and Techniques.Wiley;2007 
[22] Howe FA, Barton SJ, et al.: Metabolic profiles of human brain tumors using quantitative 
in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49(2) 223-232. 
[23] Gideon P, Henriksen O, Sperling B, et al. Early time course of N-acetylaspartate, 
creatine and phosphocreatine, and compounds containing choline in the brain after 
acute stroke. A proton magnetic resonance spectroscopy study. Stroke 1992; 23(11) 
1566-1572, 1992. 
[24] van der Graaf M: In vivo magnetic resonance spectroscopy: basic methodology and 
clinical applications. Eur Biophys J 2010; 39(4) 527-40. 
[25] Castillo M, Smith JK and Kwock L. Correlation of myo-inositol levels and grading of 
cerebral astrocytomas. AJNR Am J Neuroradiol 2000; 21(9) 1645-1649. 
[26] Mishra AM, Gupta RK, Jaggi RS, et al. Role of diffusion-weighted imaging and in vivo 
proton magnetic resonance spectroscopy in the differential diagnosis of ring-enhancing 
intracranial cystic mass lesions. J Comput Assist Tomogr 2004; 28(4) 540-547. 
[27] Kizu O, Yamada K, Nishimura T. Proton chemical shift imaging in normal pressure 
hydrocephalus. AJNR Am J Neuroradiol 2001;22(9) 1659-64. 
[28] Yeh IB, Xu M, Ng WH, et al. Central neurocytoma: typical magnetic resonance 
spectroscopy findings and atypical ventricular dissemination. Magn Reson Imaging 
2008; 26(1) 59-64. 
[29] Cecil KM. MR spectroscopy of metabolic disorders. Neuroimaging Clin N Am 2006; 
16(1) 87-116 
[30] Srinivasan R, Cunningham C, Chen A, et al. TE-averaged two-dimensional proton 
spectroscopic imaging of glutamate at 3 T. Neuroimage 2006;30(4) 1171-8. 
[31] Simister RJ, McLean MA, Barker GJ and Duncan JS: Proton MR spectroscopy of 
metabolite concentrations in temporal lobe epilepsy and effect of temporal lobe 
resection. Epilepsy Res 2009; 83(2-3): 168-176. 
 
Proton Magnetic Resonance Spectroscopy of the Central Nervous System 45 
[32] Kantarci K, Reynolds G, Petersen RC, et al. Proton MR spectroscopy in mild cognitive 
impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am J Neuroradiol 
2003; 24(5) 843-849. 
[33] Ricci R, Bacci A, Tugnoli V, et al. Metabolic findings on 3T 1H-MR spectroscopy in 
peritumoral brain edema. AJNR Am J Neuroradiol 2007; 28(7): 1287-1291. 
[34] Malhotra HS, Jain KK, Agarwal A, et al. Characterization of tumefactive demyelinating 
lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler 2009; 15(2) 
193-203. 
[35] Krishnamoorthy T, Radhakrishnan VV, Thomas B, et al. Alanine peak in central 
neurocytomas on proton MR spectroscopy. Neurora- diology 2007;49(7) 551–4. 
[36] Majos C, Alonso J, Aguilera C, et al. Proton magnetic resonance spectroscopy ((1)H 
MRS) of human brain tumours: assessment of differences between tumour types and its 
applicability in brain tumour categorization. Eur Radiol 2003;13(3) 582-591. 
[37] Yue Q, Isobe T, Shibata Y, et al. New observations concerning the interpretation of 
magnetic resonance spectroscopy of meningioma. Eur Radiol 2008; 18(12) 2901-2911. 
[38] Lehnhardt FG, Bock C, Rohn G, Ernestus RI and Hoehn M. Metabolic differences 
between primary and recurrent human brain tumors: a 1H NMR spectroscopic 
investigation. NMR Biomed 2005; 18(6): 371-382. 
[39] Kinoshita Y and Yokota A. Absolute concentrations of metabolites in human brain 
tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed 1997;10(1) 
2-12. 
[40] Shirayama Y, Obata T, Matsuzawa D, et al.: Specific metabolites in the medial prefrontal 
cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary 
study. Neuroimage 2010;49(3) 2783-2790. 
[41] An L, Zhang Y, Thomasson DM, et al.: Measurement of glutathione in normal 
volunteers and stroke patients at 3T using J-difference spectroscopy with minimized 
subtraction errors. J Magn Reson Imaging 2009; 30(2) 263-270. 
[42] Opstad KS, Provencher SW, Bell BA, et al. Detection of elevated glutathione in 
meningiomas by quantitative in vivo 1H MRS. Magn Reson Med 2003;49(4) 632-637. 
[43] Barker PB, Hearshen DO and Boska MD: Single-voxel proton MRS of the human brain 
at 1.5T and 3.0T. Magn Reson Med 2001;45(5) 765-769. 
[44] Stephenson MC, Gunner F, Napolitano A, et al.: Applications of multi-nuclear magnetic 
resonance spectroscopy at 7T. World J Radiol 2011; 3(4) 105-113. 
[45] Di Costanzo A, Trojsi F, Tosetti M, et al. High-field proton MRS of human brain. Eur J 
Radiol 2003; 48(2) 146-153. 
[46] Lange T, Dydak U, Roberts TP, Rowley HA, Bjeljac M and Boesiger P: Pitfalls in lactate 
measurements at 3T. AJNR Am J Neuroradiol 2006;27(4) 895-901. 
[47] Avdievich NI, Pan JW, Baehring JM, Spencer DD, Hetherington HP. Short echo 
spectroscopic imaging of the human brain at 7T using transceiver arrays. Magn Reson 
Med 2009;62(1)17-25.  
[48] Drost DJ, Riddle WR and Clarke GD. Proton magnetic resonance spectroscopy in the 
brain: report of AAPM MR Task Group #9. Med Phys 2002;29(9) 2177-2197. 
 Novel Frontiers of Advanced Neuroimaging 46 
[49] Hetherington HP, Chu WJ, Gonen O, Pan JW. Robust fully automated shimming of the 
human brain for high-field 1H spectroscopic imaging. Magn Reson Med 2006;56(1)26-
33.  
[50] Zhang Y, Li S, Shen J. Automatic high-order shimming using parallel columns mapping 
(PACMAP). Magn Reson Med 2009;62(4)1073-1079.  
[51] Donald W. McRobbie , Elizabeth A. Moore , Martin J. Graves , Martin R. Prince  From Image 
to Proton. Cambridge University Press; 2007 
[52] Frahm J, Bruhn H, Gyngell ML, et al. Localized high-resolution proton NMR 
spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn 
Reson Med 1989;9(1) 79–93. 
[53] Bottomley P. 1984. In U.S. Patent, Vol. 4 480 228 USA. 
[54] Duyn JH, Gillen J, Sobering G, van Zijl PCM, Moonen CTW.  Multislice proton MR 
spectroscopic imaging of the brain. Radiology 1993; 188(1) 277– 2 82. 
[55] Gruber S, Mlynarik V and Moser E. High-resolution 3D proton spectroscopic imaging 
of the human brain at 3 T: SNR issues and application for anatomy-matched voxel sizes. 
Magn Reson Med 2003;49(2) 299-306. 
[56] Haase A, Frahm J, Hanicke W, Matthei D.  1H NMR chemical shift selective imaging. 
1985; Phys Med Biol 30(4) 341–344. 
[57] Mescher M, Tannus A, O’Neil Johnson M, Garwood M. Solvent suppression using 
selective echo dephasing. J Magn Reson A 1996; 123, 226–229. 
[58] Patt SL, Sykes BD. Water eliminated Fourier transform NMR spectroscopy. J Chem 
Phys 1972; 56, 3182–3184. 
[59] Spielman DM, Pauly JM, Macovski A, Glover GH, Enzmann DR.. Lipid-suppressed 
single- and multisection proton spectroscopic imaging of the human brain. J Magn 
Reson Imaging 1992; 2(3): 253–262. 
[60] Jissendi Tchofo P and Baleriaux D: Brain (1)H-MR spectroscopy in clinical 
neuroimaging at 3T. J Neuroradiol, 2008; 36(1) 24-40 
[61] Coron A,Vanhamme L, Antoine JP,Van Hecke P,Van Huffel S. The filtering approach to 
solvent peak suppression in MRS: a critical review. J Magn Reson 2001;152(1) 26–40. 
[62] Jiru F. Introduction to post-processing techniques. Eur J Radiol 2008;67(2) 202-217, 2008. 
[63] Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and 
future prospects. Lancet Neurol 2008;7 (7) 615-625. 
[64] De Stefano N and Filippi M. MR spectroscopy in multiple sclerosis. J Neuroimaging 
2007; 17 Suppl 1: 31S-35S. 
[65] Rovira A, Leon A. MR in the diagnosis and monitoring of multiple sclerosis: an 
overview. Eur J Radiol 2008; 67 (3):409-414. 
[66] Butteriss DJ, Ismail A, Ellison DW, Birchall D.Use of serial proton magnetic resonance 
spectroscopy to differentiate low grade glioma from tumefactive plaque in a patient 
with multiple sclerosis. Br J Radiol 2003; 76 (909) 662-665 
[67] Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in 
clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004;127(6) 1361-
1369. 
 
Proton Magnetic Resonance Spectroscopy of the Central Nervous System 47 
[68] Kirov I, Patil V, Babb J, et al. MR Spectroscopy Indicates Diffuse Multiple Sclerosis 
Activity During Remission. J Neurol Neurosurg Psychiatry 2009; 80(12) 1330-6. 
[69] Kimura T, Sako K, Gotoh T, et al. In vivo single-voxel proton MR spectroscopy in brain 
lesions with ring-like enhancement. NMR Biomed 2001; 14 (6) 339-349. 
[70] Lai PH, Ho JT, Chen WL, et al. Brain abscess and necrotic brain tumor: discrimination 
with proton MR spectroscopy and diffusion weight imaging. Am J Neuroradiol 
2002;23(8)1369–77. 
[71] Kapsalaki EZ, Gotsis ED, Fountas KN (2008) The role of proton magnetic resonance 
spectroscopy in the diagnosis and categorization of cerebral abscesses. Neurosurg 
Focus 2008; 24 (6) E7. 
[72] Kadota O, Kohno K, Ohue S, et al: Discrimination of brain abscess and cystic tumor by 
in vivo proton magnetic resonance spectroscopy. Neuro Med Chir (Tokyo) 2001;41(3) 
121–126. 
[73] Lai PH, Li KT, Hsu SS, et al: Pyogenic brain abscess: findings from in vivo 1.5-t and 
11.7-t in vitro proton MR spectroscopy. AJNR Am J Neuroradiol 2005; 26(2) 279– 288. 
[74] Saunders DE. MR spectroscopy in stroke. Br Med Bull 2000; 56 (2):334-345 
[75] Graham GD, Blamire AM, Howseman AM, et al. Proton magnetic resonance 
spectroscopy of cerebral lactate and other metabolites in stroke patients. Stroke 1992; 
23(3) 333-340. 
[76] Munoz Maniega S, Cvoro V, Armitage PA, et al. Choline and creatine are not reliable 
denominators for calculating metabolite ratios in acute ischemic stroke. Stroke 2008; 39 
(9) 2467-2469. 
[77] Rumpel H, Lim WE, Chang HM, et al. Is myo-inositol a measure of glial swelling after 
stroke? A magnetic resonance study. J Magn Reson Imaging 2003; 17 (1) 11-19. 
[78] Glodzik-Sobanska L, Slowik A, Kozub J, et al. GABA in ischemic stroke. Proton 
magnetic resonance study. Med Sci Monit 2004; 10 Suppl 3:88-93. 
[79] Hajek M, Dezortova M, Krsek P. (1)H MR spectroscopy in epilepsy. Eur J Radiol 2008; 
67 (2):258-267. 
[80] Leite RA, Otaduy MC, Silva GE, et al. Diagnostic methods for extra-temporal 
neocortical focal epilepsies: present and future. Arq Neuropsiquiatr 2010; 68 (1) 119-126. 
[81] Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA. N-Acetylaspartate in 
the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007;81(2) 89-131.  
[82] Wellard RM, Briellmann RS, Prichard JW, et al. Myoinositol abnormalities in temporal 
lobe epilepsy. Epilepsia 2003; 44(6) 815–821. 
[83] Doelken MT, Stefan H, Pauli E, et al. (1)H-MRS profile in MRI positive- versus MRI 
negative patients with temporal lobe epilepsy. Seizure 2008; 17 (6):490-497. 
[84] Mueller, S. G., Schuff, N., and Weiner, M. W. Evaluation of treatment effects in 
Alzheimer’s and other neurodegenerative diseases by MRI and MRS. NMR. Biomed. 
2006; 19(6), 655–668. 
[85] Chantal, S., Braun, C. M., Bouchard, R. W., et al. Similar 1H magnetic resonance 
spectroscopic metabolic pattern in the medial temporal lobes of patients with mild 
cognitive impairment and Alzheimer disease. Brain Res. 2004; 1003(1–2), 26–35. 
 Novel Frontiers of Advanced Neuroimaging 48 
[86] Herminghaus, S., Frolich, L., Gorriz, C., et al. Brain metabolism in Alzheimer disease 
and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy. 
Psychiatry. Res. 2003; 123(3), 183–190.  
[87] Kantarci K, Jack CR, Xu YC, et al. Regional metabolic patterns in mild cognitive 
impairment and Alzheimer’s disease: a 1H MRS study. Neurology 2000;55(2) 210–217 
[88] Hattori, N., Abe, K., Sakoda, S., and Sawada, T. Proton MR spectroscopic study at 3 
Tesla on glutamate/glutamine in Alzheimer’s disease. Neuroreport 2002; 13(1), 183–186. 
[89] Clarke, C.E. & M. Lowry. 2001. Systematic review of proton magnetic resonance 
spectroscopy of the striatum in parkinsonian syndromes. Eur. J. Neurol. 2001; 8(6) 573–
577. 
[90] Rango, M. Arighi A, Bonifati C, Bresolin N.Magnetic resonance spectroscopy in 
Parkinson’s disease and parkinsonian syndromes. Funct. Neurol. 2007; 22(2) 75–79. 
[91] Hu MT, Taylor-Robinson SD, Chaudhuri KR, et al. Evidence for cortical dysfunction in 
clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy 
study. J Neurol Neurosurg Psychiatry 1999;67(1) 20–26.  
[92] Choe BY, Park JW, Lee KS, et al. Neuronal laterality in Parkinson's disease with 
unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest Radial 1998; 
33(8) 450–455. 
[93] Taylor-Robinson SD, Turjanski N, Bhattacharya S, et al. A proton magnetic resonance 
spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metab 
Brain Dis 1999;14(1) 45–55. 
[94] Griffith HR, den Hollander JA, Okonkwo OC et al.  Brain N-acetylaspartate is reduced in 
Parkinson disease with dementia. Alzheimer. Dis. Assoc. Disord. 2008; 22(1) 54–60. 
[95] Summerfield, C. et al. 2002. Dementia in Parkinson disease: a proton magnetic 
resonance spectroscopy study. Arch. Neurol.2002; 59(9) 1415–1420. 
[96] Yuh EL, Barkovich AJ, Gupta N.  Imaging of ependymomas: MRI and CT. Childs Nerv 
Syst 2009; 25(10) 1203-13. 
[97] Rijpkema, M., J. Schuuring, et al. Characterization of oligodendrogliomas using short 
echo time 1H MR spectroscopic imaging. NMR Biomed 2003;16(1): 12-8. 
[98] Majos, C., C. Aguilera, et al. In vivo proton magnetic resonance spectroscopy of 
intraventricular tumours of the brain." Eur Radiol 2009;19(8): 2049-59. 
[99] Porto, L., M. Kieslich, et al. MR spectroscopy differentiation between high and low 
grade astrocytomas: a comparison between paediatric and adult tumours. Eur J 
Paediatr Neurol 2011; 15(3) 214-21. 
[100] Law, M., S. Yang, et al. Glioma grading: sensitivity, specificity, and predictive values 
of perfusion MR imaging and proton MR spectroscopic imaging compared with 
conventional MR imaging. AJNR Am J Neuroradiol 2003; 24(10) 1989-98. 
[101] Server, A., B. Kulle, et al. Measurements of diagnostic examination performance using 
quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the 
preoperative evaluation of tumor grade in cerebral gliomas." Eur J Radiol. 2011 
Nov;80(2) 462-70. 
 
Proton Magnetic Resonance Spectroscopy of the Central Nervous System 49 
[102] Server, A., R. Josefsen, et al. Proton magnetic resonance spectroscopy in the distinction 
of high-grade cerebral gliomas from single metastatic brain tumors." Acta Radiol 2010; 
51(3) 316-25. 
[103] Cha, S. Neuroimaging in neuro-oncology. Neurotherapeutics 2009; 6(3): 465-77. 
[104] Chawla, S., Y. Zhang, et al. Proton magnetic resonance spectroscopy in differentiating 
glioblastomas from primary cerebral lymphomas and brain metastases. J Comput Assist 
Tomogr 2010; 34(6) 836-41. 
[105] Law, M., S. Cha, et al. High-grade gliomas and solitary metastases: differentiation by 
using perfusion and proton spectroscopic MR imaging. Radiology 2002;222(3) 715-21. 
[106] Opstad, K. S., M. M. Murphy, et al. Differentiation of metastases from high-grade 
gliomas using short echo time 1H spectroscopy. J Magn Reson Imaging 2004; 20(2) 187-
92. 
[107] Sjobakk, T. E., R. Johansen, et al. Metabolic profiling of human brain metastases using 
in vivo proton MR spectroscopy at 3T. BMC Cancer 2007; 7: 141. 
[108] Chernov, M. F., Y. Ono, et al. Comparison of (1)H-MRS-detected metabolic 
characteristics in single metastatic brain tumors of different origin. Brain Tumor Pathol 
2006; 23(1): 35-40. 
[109] Hakyemez B, Yildirim N, Erdogan C, et al. Meningiomas with conventional MRI 
findings resembling intraaxial tumors: can perfusion-weighted MRI be helpful in 
differentiation? Neuroradiology2006; 48(10) 695-702. 
[110] Tugnoli V, Schenetti L, Mucci A, et al. Ex vivo HR-MAS MRS of human meningiomas: 
a comparison with in vivo 1H MR spectra. Int J Mol Med. 2006;18(5) 859-69. 
[111] Weber, M. A., S. Zoubaa, et al. Diagnostic performance of spectroscopic and perfusion 
MRI for distinction of brain tumors. Neurology 2006; 66(12): 1899-906. 
[112] Tang, Y.Z., Booth, T.C., Bhogal, P. et al. Imaging of primary central nervous system 
lymphoma. Clin Radiol 2011; 66(8) 768-777. 
[113] Koeller KK, Sandberg GD. Cerebral intraventricular neoplasms: radiologic–pathologic 
correlation. Radiographics 2002;22:1473–505. 
[114] Kim DG, Choe WJ, Chang KH, et al. In vivo proton magnetic resonance spectroscopy 
of central neurocytomas. Neurosurgery 2000; 46 (2) 329-333 
[115] Shah T, Jayasundar R, Singh VP, Sarkar C. MRS characterization of central 
neurocytomas using glycine. NMR Biomed 2011; 24 (10) 1408-1413. 
[116] Chuang MT, Lin WC, Tsai HY, et al. 3-T proton magnetic resonance spectroscopy of 
central neurocytoma: 3 case reports and review of the literature. J Comput Assist 
Tomogr 2005; 29 (5) 683-688. 
[117] Yu A, Li K, Li H. Value of diagnosis and differential diagnosis of MRI and MR 
spectroscopy in gliomatosis cerebri. Eur J Radiol 2006; 59 (2) 216-221.  
[118] Arai M, Kashihara K, Kaizaki Y, et al. Gliomatosis cerebri: report of 3 cases and review 
of recent literatures. No To Shinkei 2003;55(10) 890–7.  
[119] Bendszus M, Warmuth-Metz M, Klein R, et al. MR spectroscopy in gliomatosis cerebri. 
AJNR Am J Neuroradiol 2000; 21 (2) 375-380 
[120] Sener RN. Proton MR spectroscopy of craniopharyngiomas. Comput Med Imaging 
Graph 2001; 25 (5):417-422. 
 Novel Frontiers of Advanced Neuroimaging 50 
[121] Stadlbauer A, Buchfelder M, Nimsky C, Saeger W, Salomonowitz E, Pinker K, Richter 
G, Akutsu H, Ganslandt O et al. Proton magnetic resonance spectroscopy in pituitary 
macroadenomas: preliminary results. J Neurosurg 2008; 109 (2) 306-312. 
